{"nctId":"NCT00731679","briefTitle":"Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","startDateStruct":{"date":"2008-07"},"conditions":["Non-Constipation Irritable Bowel Syndrome"],"count":623,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Rifaximin","type":"EXPERIMENTAL","interventionNames":["Drug: Rifaximin"]}],"interventions":[{"name":"Rifaximin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed IBS diagnosis per Rome II for diagnosis of IBS.\n* Colonoscopy within 2 years as part of IBS diagnostic evaluation.\n* Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.\n\nExclusion Criteria:\n\n* Symptoms of constipation.\n* History of other gastrointestinal diseases.\n* Type 1 or 2 diabetes.\n* Lactose intolerance not controlled by lactose-free diet.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).","description":"The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of \"yes\" to the following question, which was asked weekly (every 7 days): \"In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \\[Yes/No\\]\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).","description":"The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of \"yes\" to the following question, which was asked weekly (every 7 days): \"In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \\[Yes/No\\].\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":314},"commonTop":["Abdominal pain","Nausea","Headache","Diarrhoea","Nasopharyngitis"]}}}